CPMV
Price
$0.49
Change
+$0.13 (+36.11%)
Updated
Jun 27 closing price
Capitalization
3.57M
NVAX
Price
$6.37
Change
-$0.13 (-2.00%)
Updated
Jun 27 closing price
Capitalization
1.03B
37 days until earnings call
Interact to see
Advertisement

CPMV vs NVAX

Header iconCPMV vs NVAX Comparison
Open Charts CPMV vs NVAXBanner chart's image
Mosaic ImmunoEngineering
Price$0.49
Change+$0.13 (+36.11%)
Volume$200
Capitalization3.57M
Novavax
Price$6.37
Change-$0.13 (-2.00%)
Volume$3.8M
Capitalization1.03B
CPMV vs NVAX Comparison Chart in %
Loading...
CPMV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPMV vs. NVAX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPMV is a Hold and NVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CPMV: $0.49 vs. NVAX: $6.38)
Brand notoriety: CPMV: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPMV: 16% vs. NVAX: 39%
Market capitalization -- CPMV: $3.57M vs. NVAX: $1.03B
CPMV [@Biotechnology] is valued at $3.57M. NVAX’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPMV’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • CPMV’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, CPMV is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPMV’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • CPMV’s TA Score: 3 bullish, 3 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CPMV is a better buy in the short-term than NVAX.

Price Growth

CPMV (@Biotechnology) experienced а +50.20% price change this week, while NVAX (@Biotechnology) price change was -0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.03B) has a higher market cap than CPMV($3.57M). NVAX YTD gains are higher at: -20.709 vs. CPMV (-29.621). NVAX has higher annual earnings (EBITDA): 555M vs. CPMV (-729.66K). NVAX has more cash in the bank: 731M vs. CPMV (85.9K). CPMV has less debt than NVAX: CPMV (1.61M) vs NVAX (229M). NVAX has higher revenues than CPMV: NVAX (1.22B) vs CPMV (0).
CPMVNVAXCPMV / NVAX
Capitalization3.57M1.03B0%
EBITDA-729.66K555M-0%
Gain YTD-29.621-20.709143%
P/E RatioN/A2.32-
Revenue01.22B-
Total Cash85.9K731M0%
Total Debt1.61M229M1%
FUNDAMENTALS RATINGS
CPMV vs NVAX: Fundamental Ratings
CPMV
NVAX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4185
P/E GROWTH RATING
1..100
6354
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPMV's Valuation (83) in the null industry is in the same range as NVAX (87) in the Biotechnology industry. This means that CPMV’s stock grew similarly to NVAX’s over the last 12 months.

CPMV's Profit vs Risk Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that CPMV’s stock grew similarly to NVAX’s over the last 12 months.

CPMV's SMR Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that CPMV’s stock grew similarly to NVAX’s over the last 12 months.

CPMV's Price Growth Rating (41) in the null industry is somewhat better than the same rating for NVAX (85) in the Biotechnology industry. This means that CPMV’s stock grew somewhat faster than NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (54) in the Biotechnology industry is in the same range as CPMV (63) in the null industry. This means that NVAX’s stock grew similarly to CPMV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPMVNVAX
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CPMV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KKR134.292.35
+1.78%
KKR & Co
HR15.760.21
+1.35%
Healthcare Realty Trust
SEI28.980.22
+0.76%
Solaris Energy Infrastructure Inc
GENI10.380.02
+0.19%
Genius Sports Limited
JUNS1.05-0.03
-2.78%
Jupiter Neurosciences Inc

CPMV and

Correlation & Price change

A.I.dvisor tells us that CPMV and QTTB have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPMV and QTTB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPMV
1D Price
Change %
CPMV100%
+37.08%
QTTB - CPMV
23%
Poorly correlated
-5.16%
NVAX - CPMV
21%
Poorly correlated
-1.92%
PPTDF - CPMV
21%
Poorly correlated
N/A
SIGY - CPMV
6%
Poorly correlated
N/A
CLYYF - CPMV
3%
Poorly correlated
N/A
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.92%
MRNA - NVAX
45%
Loosely correlated
-1.38%
ARCT - NVAX
43%
Loosely correlated
-7.49%
BNTX - NVAX
42%
Loosely correlated
+0.55%
CRSP - NVAX
40%
Loosely correlated
N/A
XNCR - NVAX
39%
Loosely correlated
-3.10%
More